NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. (NRSN): 1 pipeline candidate · ~0 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
0.1 months
D/E -1.66 · 0% dilution
Lead: Phase 2
1 candidate
N/A
N/A
A transparent, data-derived signal for NeuroSense Therapeutics Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$24.9M
Cash
$166K
Quarterly Burn
$7.7M
Runway
0.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| primec | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
9
Total value held
$140K
| Holder | Shares | Value |
|---|---|---|
| two sigma investments, lp | 44,445 | $34K |
| meitav investment house ltd | 40,000 | $30K |
| jane street group, llc | 28,670 | $22K |
| commonwealth equity services, llc | 22,775 | $17K |
| pnc financial services group, inc. | 21,150 | $16K |
| geode capital management, llc | 15,870 | $12K |
| creative planning | 11,911 | $9K |
| jones financial companies lllp | 1,000 | $731 |
| sbi securities co., ltd. | 265 | $200 |
Frequently asked questions
How many drug candidates are in NeuroSense Therapeutics Ltd.'s pipeline?
NeuroSense Therapeutics Ltd. (NRSN) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is NeuroSense Therapeutics Ltd.'s lead drug candidate?
NeuroSense Therapeutics Ltd.'s most advanced tracked candidate is primec (Phase 2) for Alzheimer Disease; Amyotrophic Lateral Sclerosis.
What is NeuroSense Therapeutics Ltd.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, NeuroSense Therapeutics Ltd. has approximately 0.1 months of cash runway.
What is NeuroSense Therapeutics Ltd.'s market capitalization?
NeuroSense Therapeutics Ltd.'s market capitalization is approximately $24.9M.
Who is the CEO of NeuroSense Therapeutics Ltd.?
Mr. Alon Ben-Noon is the chief executive officer of NeuroSense Therapeutics Ltd. (NRSN).
Get the full picture on NeuroSense Therapeutics Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.